About Assembly Biosciences (NASDAQ:ASMB)
Assembly Biosciences, Inc. operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States. It is involved in the development of core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. In addition, it engages in the development of product candidates for various disease indications, such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, non-alcoholic steatohepatitis, immuno-oncology, and clostridium difficile infections by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of selected microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ASMB
CUSIP92282210
Phone317-210-9311
Debt
Debt-to-Equity RatioN/A
Current Ratio9.13%
Quick Ratio9.13%
Price-To-Earnings
Trailing P/E Ratio-18.33
Forward P/E Ratio-14.44
P/E GrowthN/A
Sales & Book Value
Annual Sales$9.02 million
Price / Sales99.73
Cash FlowN/A
Price / CashN/A
Book Value$5.62 per share
Price / Book7.83
Profitability
EPS (Most Recent Fiscal Year)($2.41)
Net Income$-42,800,000.00
Net Margins-474.65%
Return on Equity-60.16%
Return on Assets-31.79%
Miscellaneous
Employees79
Outstanding Shares20,430,000
Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions
What is Assembly Biosciences' stock symbol?
Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."
How were Assembly Biosciences' earnings last quarter?
Assembly Biosciences (NASDAQ:ASMB) announced its quarterly earnings data on Thursday, March, 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter. The biopharmaceutical company earned $3.32 million during the quarter. Assembly Biosciences had a negative net margin of 474.65% and a negative return on equity of 60.16%. View Assembly Biosciences' Earnings History.
What price target have analysts set for ASMB?
3 equities research analysts have issued 1 year price targets for Assembly Biosciences' shares. Their forecasts range from $35.00 to $75.00. On average, they expect Assembly Biosciences' stock price to reach $53.3333 in the next year. View Analyst Ratings for Assembly Biosciences.
Are investors shorting Assembly Biosciences?
Assembly Biosciences saw a decline in short interest during the month of March. As of March 15th, there was short interest totalling 355,682 shares, a decline of 34.0% from the February 28th total of 539,065 shares. Based on an average daily trading volume, of 189,244 shares, the short-interest ratio is currently 1.9 days. Currently, 2.1% of the shares of the stock are short sold.
Who are some of Assembly Biosciences' key competitors?
Some companies that are related to Assembly Biosciences include Blueprint Medicines (BPMC), Ligand Pharmaceuticals (LGND), Tesaro (TSRO), Array BioPharma (ARRY), Emergent BioSolutions (EBS), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Evotec A.G. (EVTCY), Ironwood Pharmaceuticals (IRWD), Acadia Pharmaceuticals (ACAD), Clovis Oncology (CLVS), Supernus Pharmaceuticals (SUPN), Puma Biotechnology (PBYI) and Portola Pharmaceuticals (PTLA).
Who are Assembly Biosciences' key executives?
Assembly Biosciences' management team includes the folowing people:
- Mr. Derek A. Small, Co-Founder, Pres, CEO & Director (Age 42)
- Dr. Richard J. Colonno Ph.D., Chief Scientific Officer (Age 68)
- Mr. Thomas E. Rollins M.S., M.B.A., Chief Devel. Officer and Head of the Microbiome Program (Age 62)
- Mr. David J. Barrett CPA, Strategic Advisor Role (Age 42)
- Dr. Miguel S. Barbosa Ph.D., Strategic Advisor (Age 60)
Has Assembly Biosciences been receiving favorable news coverage?
Press coverage about ASMB stock has trended somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Assembly Biosciences earned a coverage optimism score of 0.11 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 47.48 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Assembly Biosciences?
Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Assembly Biosciences' stock price today?
One share of ASMB stock can currently be purchased for approximately $44.37.
How big of a company is Assembly Biosciences?
Assembly Biosciences has a market capitalization of $890.93 million and generates $9.02 million in revenue each year. The biopharmaceutical company earns $-42,800,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Assembly Biosciences employs 79 workers across the globe.
How can I contact Assembly Biosciences?
Assembly Biosciences' mailing address is 11711 NORTH MERIDIAN STREET SUITE 310, CARMEL IN, 46032. The biopharmaceutical company can be reached via phone at 317-210-9311 or via email at [email protected]
MarketBeat Community Rating for Assembly Biosciences (ASMB)
MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote "Outperform" if you believe ASMB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASMB will underperform the S&P 500 over the long term. You may vote once every thirty days.
Assembly Biosciences (NASDAQ:ASMB) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Assembly Biosciences in the last 12 months. Their average twelve-month price target is $53.3333, suggesting that the stock has a possible upside of 21.13%. The high price target for ASMB is $75.00 and the low price target for ASMB is $35.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Buy | Buy | Buy |
| Consensus Rating Score: | 2.33 | 2.67 | 2.67 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $53.3333 | $48.3333 | $40.00 | $35.00 |
| Price Target Upside: | 21.13% upside | 15.78% downside | 10.93% downside | 13.20% upside |
Assembly Biosciences (NASDAQ:ASMB) Consensus Price Target History
Assembly Biosciences (NASDAQ:ASMB) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
Assembly Biosciences (NASDAQ:ASMB) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Assembly Biosciences (NASDAQ ASMB) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 19.60%
Institutional Ownership Percentage: 76.34%
Assembly Biosciences (NASDAQ ASMB) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/2/2018 | William R Ringo | Director | Sell | 1,000 | $49.32 | $49,320.00 | 20,465 |  |
| 3/1/2018 | William R Ringo | Director | Sell | 1,000 | $56.37 | $56,370.00 | | |
| 2/1/2018 | William R Ringo | Director | Sell | 1,000 | $46.86 | $46,860.00 | | |
| 1/2/2018 | William R Ringo | Director | Sell | 1,000 | $45.04 | $45,040.00 | | |
| 12/1/2017 | William R Ringo | Director | Sell | 1,000 | $49.37 | $49,370.00 | 20,465 | |
| 11/1/2017 | William R Ringo | Director | Sell | 1,000 | $29.55 | $29,550.00 | | |
| 10/16/2017 | William R Ringo | Director | Sell | 1,000 | $33.70 | $33,700.00 | | |
| 2/11/2016 | Derek A. Small | CEO | Buy | 10,000 | $5.53 | $55,300.00 | 634,391 | |
| 5/27/2014 | Russell H Ellison | CEO | Buy | 13,000 | $0.92 | $11,960.00 | | |
| 5/23/2014 | David Jonathan Barrett | CFO | Buy | 6,980 | $0.86 | $6,002.80 | | |
| 5/23/2014 | Russell H Ellison | CEO | Buy | 20,000 | $0.91 | $18,200.00 | | |
| 5/21/2014 | Russell Ellison | CEO | Buy | 10,000 | $0.87 | $8,700.00 | 25,000 | |
| 5/20/2014 | David Jonathan Barrett | CFO | Buy | 40,000 | $0.88 | $35,200.00 | 40,000 | |
| 2/5/2013 | Russell H Ellison | CEO | Buy | 15,000 | $2.55 | $38,250.00 | | |
(Data available from 1/1/2013 forward)
Assembly Biosciences (NASDAQ ASMB) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Brokerages Expect Assembly Biosciences (ASMB) Will Post Quarterly Sales of $1.88 Million
www.americanbankingnews.com - April 21 at 4:52 AM |
| Analysts Anticipate Assembly Biosciences (ASMB) Will Announce Earnings of -$0.76 Per Share
www.americanbankingnews.com - April 19 at 5:19 AM |
| Assembly Biosciences (ASMB) Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 18 at 10:42 AM |
| Assembly Biosciences (ASMB) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 15 at 7:15 AM |
| BidaskClub Upgrades Assembly Biosciences (ASMB) to "Sell"
www.americanbankingnews.com - April 13 at 5:29 PM |
 | Chardan: Assembly Biosciences Hep B Antiviral Data 'Positive,' But Undifferentiated From Competitor Johnson & Johnson
finance.yahoo.com - April 13 at 3:46 PM |
| Assembly Biosciences (ASMB) Downgraded by Chardan Capital to "Neutral"
www.americanbankingnews.com - April 13 at 10:37 AM |
 | Assembly Bio's lead candidate shows positive action in early-stage HBV studies
seekingalpha.com - April 12 at 11:19 AM |
| Was Assembly Biosciences Inc’s (NASDAQ:ASMB) Earnings Growth Better Than The Industry’s?
finance.yahoo.com - April 12 at 11:19 AM |
| Assembly Biosciences (ASMB) Upgraded at BidaskClub
www.americanbankingnews.com - April 12 at 10:22 AM |
 | Assembly Biosciences to Host Conference Call on April 12 to Review ABI-H0731 Interim Phase 1b Data
www.nasdaq.com - April 11 at 11:00 AM |
| Assembly Bio conference call tomorrow to review ABI-H0731 data
seekingalpha.com - April 11 at 11:00 AM |
| Assembly Biosciences (ASMB) Cut to Sell at BidaskClub
www.americanbankingnews.com - April 4 at 9:55 AM |
| Assembly Biosciences (ASMB) Expected to Post Quarterly Sales of $1.88 Million
www.americanbankingnews.com - April 4 at 4:28 AM |
 | Assembly Biosciences (ASMB) Says ABI-H0731 Phase 1b Interim Data Accepted as a Late-Breaker Poster at EASL
www.streetinsider.com - April 3 at 10:42 AM |
| Assembly Biosciences Appoints Jackie Papkoff, PhD, Senior Vice President, Chief Scientific Officer Microbiome
finance.yahoo.com - April 3 at 10:42 AM |
| William R. Ringo Sells 1,000 Shares of Assembly Biosciences (ASMB) Stock
www.americanbankingnews.com - April 2 at 10:41 PM |
 | Active-Investors: Blog Exposure - Assembly Biosciences to Present ABI-H0731 Phase-1b Interim Data at The International Liver Congress
www.finanznachrichten.de - April 2 at 10:47 AM |
| Assembly Biosciences Inc (ASMB) Expected to Announce Earnings of -$0.79 Per Share
www.americanbankingnews.com - April 2 at 5:12 AM |
| Jefferies Group Initiates Coverage on Assembly Biosciences (ASMB)
www.americanbankingnews.com - April 1 at 10:48 AM |
| Assembly Biosciences (ASMB) & Blueprint Medicines (BPMC) Financial Survey
www.americanbankingnews.com - March 31 at 7:50 AM |
| Assembly Biosciences Inc (ASMB) Short Interest Update
www.americanbankingnews.com - March 31 at 3:18 AM |
| Assembly Biosciences Sees Unusually High Options Volume (ASMB)
www.americanbankingnews.com - March 30 at 7:07 AM |
| Assembly Biosciences (ASMB) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - March 26 at 3:13 PM |
| Assembly Biosciences (ASMB) Downgraded by BidaskClub to Buy
www.americanbankingnews.com - March 23 at 8:28 PM |
| Assembly Biosciences Inc (ASMB) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - March 21 at 10:44 AM |
| $1.68 Million in Sales Expected for Assembly Biosciences Inc (ASMB) This Quarter
www.americanbankingnews.com - March 18 at 9:28 AM |
| BidaskClub Upgrades Assembly Biosciences (ASMB) to Strong-Buy
www.americanbankingnews.com - March 17 at 7:16 PM |
| Assembly Biosciences (ASMB) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 14 at 5:32 PM |
| Assembly Biosciences Target of Unusually Large Options Trading (ASMB)
www.americanbankingnews.com - March 14 at 7:33 AM |
| Assembly Biosciences (ASMB) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 13 at 5:48 PM |
| Assembly Biosciences Announces Additions to Management Team and Board of Directors
finance.yahoo.com - March 12 at 9:16 AM |
| Assembly Biosciences Inc Expected to Earn Q1 2019 Earnings of ($0.82) Per Share (ASMB)
www.americanbankingnews.com - March 12 at 7:15 AM |
| Assembly Biosciences Inc to Post Q2 2018 Earnings of ($0.77) Per Share, Jefferies Group Forecasts (ASMB)
www.americanbankingnews.com - March 12 at 3:40 AM |
| Assembly Biosciences (ASMB) PT Raised to $75.00 at Jefferies Group
www.americanbankingnews.com - March 8 at 6:34 PM |
| Assembly Biosciences to Present at Cowen’s 38th Annual Healthcare Conference
finance.yahoo.com - March 5 at 11:01 AM |
| Bogle Investment Management L P DE Acquires New Stake in Assembly Biosciences Inc (ASMB)
www.americanbankingnews.com - March 4 at 4:58 AM |
| Insider Selling: Assembly Biosciences Inc (ASMB) Director Sells 1,000 Shares of Stock
www.americanbankingnews.com - March 2 at 7:16 PM |
| Zacks: Brokerages Anticipate Assembly Biosciences Inc (ASMB) Will Announce Quarterly Sales of $1.68 Million
www.americanbankingnews.com - March 1 at 11:24 AM |
| Assembly Biosciences Inc (ASMB) Shares Bought by EAM Investors LLC
www.americanbankingnews.com - February 28 at 1:56 PM |
| Assembly Biosciences Inc (ASMB) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - February 24 at 9:54 AM |
| Victory Capital Management Inc. Purchases 11,830 Shares of Assembly Biosciences Inc (ASMB)
www.americanbankingnews.com - February 24 at 4:52 AM |
| Stock Traders Buy High Volume of Call Options on Assembly Biosciences (ASMB)
www.americanbankingnews.com - February 22 at 7:44 AM |
| Brokerages Anticipate Assembly Biosciences Inc (ASMB) Will Announce Quarterly Sales of $1.68 Million
www.americanbankingnews.com - February 12 at 5:28 AM |
| Investor Expectations to Drive Momentum within Regal Beloit, Kaiser Aluminum, AngioDynamics, Mulesoft, Assembly Biosciences, and Woodward — Discovering Underlying Factors of Influence
finance.yahoo.com - February 6 at 8:30 AM |
| Assembly Biosciences (ASMB) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - February 3 at 2:36 PM |
| Assembly Biosciences Inc (ASMB) Director Sells $46,860.00 in Stock
www.americanbankingnews.com - February 2 at 10:02 PM |
| Assembly Biosciences Inc (ASMB) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - January 30 at 9:39 AM |
| Zacks: Brokerages Expect Assembly Biosciences Inc (ASMB) Will Post Earnings of -$0.79 Per Share
www.americanbankingnews.com - January 24 at 1:36 PM |
| Commit To Purchase Assembly Biosciences At $40, Earn 41.3% Annualized Using Options
www.nasdaq.com - January 24 at 8:51 AM |
Assembly Biosciences (NASDAQ:ASMB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Assembly Biosciences (NASDAQ:ASMB) Income Statement, Balance Sheet and Cash Flow Statement
Assembly Biosciences (NASDAQ ASMB) Stock Chart for Thursday, April, 26, 2018
Loading chart…
